Restoring regulation - IL-2 therapy in systemic lupus erythematosus

被引:39
|
作者
Humrich, Jens Y. [1 ]
Riemekasten, Gabriela [1 ]
机构
[1] Univ Hosp Schleswig Holstein, Dept Rheumatol, Campus Lubeck,Ratzeburger Allee 160, D-23538 Lubeck, Germany
关键词
SLE; regulatory T cell; interleukin-2; immunotherapy; tolerance; immune homeostasis; systemic lupus erythematosus; LOW-DOSE INTERLEUKIN-2; RESPONSIVE ELEMENT MODULATOR; T-CELLS; AUTOIMMUNE-DISEASE; SELF-TOLERANCE; VIVO EXPANSION; PRONE MICE; EX-VIVO; FOXP3; EXPRESSION;
D O I
10.1080/1744666X.2016.1199957
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: The pathogenesis of systemic lupus erythematosus (SLE) involves an acquired deficiency of the cytokine IL-2, an essential growth and survival factor for regulatory T cells (Treg), which play an important role in the control of autoimmunity in SLE. In contrast to currently available therapies that broadly suppress the immune system, low-dose IL-2 therapy in SLE aims to compensate the pre-existing IL-2 deficiency and thus to restore a physiological state, where Treg can regain their ability to efficiently counteract autoimmunity.Areas covered: Here we summarize key findings that led to the development of this novel therapeutic concept and will highlight the key rationales for the clinical translation of low-dose IL-2 therapy in SLE.Expert commentary: The concept of low-dose IL-2 therapy in SLE has evolved from pathophysiological findings and thus can be considered a selective biological treatment strategy in SLE. Preliminary results from phase I/II studies are promising by proving selective Treg expansion and by providing first evidence for the clinical efficacy of low-dose IL-2 therapy in SLE.
引用
收藏
页码:1153 / 1160
页数:8
相关论文
共 50 条
  • [31] EXERCISE THERAPY IN SYSTEMIC LUPUS ERYTHEMATOSUS
    Bostrom, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 39 - 39
  • [32] Belimumab Therapy in Systemic Lupus Erythematosus
    Moncef Zouali
    Eugene A. Uy
    BioDrugs, 2013, 27 : 225 - 235
  • [33] THERAPY OF SYSTEMIC LUPUS-ERYTHEMATOSUS
    BANGO, MY
    NUNEZ, JAV
    GEABANACLOCHE, JC
    PIZARRO, YR
    REVISTA CLINICA ESPANOLA, 1995, 195 (01): : 50 - 61
  • [34] Belimumab Therapy in Systemic Lupus Erythematosus
    Zouali, Moncef
    Uy, Eugene A.
    BIODRUGS, 2013, 27 (03) : 225 - 235
  • [35] Methotrexate therapy in systemic lupus erythematosus
    Sato, EI
    LUPUS, 2001, 10 (03) : 162 - 164
  • [36] Perspectives of Systemic Lupus Erythematosus Therapy
    Borysewicz, Krzysztof
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2008, 17 (04): : 433 - 439
  • [37] Anticytokine therapy in systemic lupus erythematosus
    Yoo, D-H
    LUPUS, 2010, 19 (12) : 1460 - 1467
  • [38] Gene therapy in systemic lupus erythematosus
    Kyttaris, VC
    Juang, YT
    Tsokos, GC
    LUPUS, 2004, 13 (05) : 353 - 358
  • [39] Biological Therapy in Systemic Lupus Erythematosus
    Postal, Mariana
    Costallat, Lilian T. L.
    Appenzeller, Simone
    INTERNATIONAL JOURNAL OF RHEUMATOLOGY, 2012, 2012
  • [40] Cellular therapy of systemic lupus erythematosus
    Tyndall, A.
    LUPUS, 2009, 18 (05) : 387 - 393